504437-66-5

Basic information

• Product Name: Acetamide, N-[[(5S)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen yl]-2-oxo-5-oxazolidinyl]methyl]-
• CAS NO: 504437-66-5
• Molecular Formula: C18H24BFN2O5
• Molecular Weight: 378.208
• Mol File: 504437-66-5.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: Acetamide, N-[[(5S)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen yl]-2-oxo-5-oxazolidinyl]methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-[[(5S)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen yl]-2-oxo-5-oxazolidinyl]methyl]-(504437-66-5)
• EPA Substance Registry System: Acetamide, N-[[(5S)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen yl]-2-oxo-5-oxazolidinyl]methyl]-(504437-66-5)

Safety Data

• Hazardous Substances Data: 504437-66-5(Hazardous Substances Data)

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 149524-45-8 (S)-N-[3-(3-fluoro-4-iodophenyl)-2-oxo-1,3-oxazolidine-5-ylmethyl]acetamide 
• 396076-65-6 (4-bromo-3-fluoro-phenyl)-carbamic acid methyl ester 
• 1032827-78-3 (S)-2-((3-(4-bromo-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)isoindoline-1,3-dione 
• 487041-08-7 (5R)-3-(3-fluoro-4-iodo-phenyl)-5-hydroxymethyl-1,3-oxazolidin-2-one 
• 149524-42-5 (5R)-3-(3-fluorophenyl)-5-hydroxymethyloxazolidin-2-one 
• 149524-47-0 N-(carbobenzyloxy)-3-fluoroaniline 
• 372-19-0 meta-fluoroaniline 
• 627543-03-7 (5S)-5-aminomethyl-3-(3-fluoro-4-iodophenyl)-oxazolidin-2-one 
• 856677-03-7 (S)-5-(aminomethyl)-3-(4-bromo-3-fluorophenyl)oxazolidin-2-one 
• 856677-05-9 (5S)-N-[[3-(3-fluoro-4-bromophenyl)-2-oxo-oxazolidin-5-yl]methyl]acetamide 
• 856677-01-5 (R)-5-(azidomethyl)-3-(4-bromo-3-fluorophenyl)oxazolidin-2-one 
• 856676-99-8 methanesulfonic acid (5R)-3-(4-bromo-3-fluorophenyl)-2-oxooxazolidin-5-ylmethyl ester 
• 444335-16-4 (R)-3-(4-bromo-3-fluorophenyl)-5-(hydroxylmethyl)oxazolidin-2-one 

Downstream Products

• 1401341-60-3 C₂₀H₂₁FN₆O₃*ClH 
• 1401341-61-4 C₂₁H₂₃FN₆O₃ 
• 1401341-63-6 C₂₄H₂₇FN₆O₅ 
• 1401341-64-7 C₂₂H₂₅FN₆O₄ 
• 1401341-65-8 C₂₃H₂₅FN₆O₃ 
• 1401341-66-9 C₂₃H₂₃FN₆O₃ 
• 1401341-67-0 C₂₆H₃₁FN₆O₅ 
• 1401341-69-2 C₂₂H₂₃FN₆O₅ 
• 1401341-70-5 C₂₄H₂₅FN₆O₆ 
• 1401341-71-6 C₂₆H₂₇FN₆O₈ 
• 1401341-72-7 C₃₆H₃₆FN₆O₈P 
• 1401341-74-9 C₂₂H₂₄FN₇O₄ 
• 1401342-11-7 C₂₀H₂₁FN₆O₃*ClH 
• 1401342-12-8 C₂₂H₂₃FN₆O₅ 

Relevant articles and documents

Design, synthesis and antibacterial evaluation of novel oxazolidinone derivatives nitrogen-containing fused heterocyclic moiety

A series of novel oxazolidinone derivatives with nitrogen-containing fused heterocyclic moiety were designed and synthesized in this article. Their antibacterial activities were measured against S. aureus, MRSA and MSSA by MIC assay. Most of them exhibite

Optimization of biaryloxazolidinone as promising antibacterial agents against antibiotic-susceptible and antibiotic-resistant gram-positive bacteria

We previously discovered a series of novel biaryloxazolidinone analogues bearing a hydrazone moiety with potent antibacterial activity. However, the most potent compound OB-104 exhibited undesirable chemical and metabolic instability. Herein, novel biaryloxazolidinone analogues were designed and synthesized to improve the chemical and metabolic stability. Compounds 6a-1, 6a-3, 14a-1, 14a-3 and 14a-7 showed significant antibacterial activity against the tested Gram-positive bacteria as compared to radezolid and linezolid. Further studies indicated that most of them exhibited improved water solubility and chemical stability. Compound 14a-7 had MIC values of 0.125–0.25 μg/mL against all tested Gram-positive bacteria, and showed excellent antibacterial activity against clinical isolates of antibiotic-susceptible and antibiotic-resistant bacteria. Moreover, it was stable in human liver microsome. From a safety viewpoint, it showed non-cytotoxic activity against hepatic cell and exhibited lower inhibitory activity against human MAO-A compared to linezolid. The potent antibacterial activity and all these improved drug-likeness properties and safety profile suggested that compound 14a-7 might be a promising drug candidate for further investigation.

NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME

Disclosed is a novel oxazolidinone derivative represented by Formula 1 above, in particular, a novel oxazolidinone compound having a cyclic amidoxime or cyclic amidrazone group. In Formula 1, R and Q are the same as defined in the detailed description. In addition, disclosed is a pharmaceutical composition for an antibiotic which includes the novel oxazolidinone derivative of Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The novel oxazolidinone derivative, the prodrug thereof, the hydrate thereof, the solvate thereof, the isomer thereof, and the pharmaceutically acceptable salt thereof have broad antibacterial spectrum against resistant bacteria, low toxicity and strong antibacterial effects against Gram-positive and Gram-negative bacteria and thus may be effectively used as antibiotics.